Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 6/7/26 | Eli Lilly and Company (LLY) | Xinermei for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/7/26 | Eli Lilly and Company (LLY) | Xinermei for Diabetes Mellitus, Type II | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/7/26 | Boehringer | survodutide for Obesity | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/6/26 | Akcea Therapeutics | Tryngolza for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
| 6/6/26 | Akcea Therapeutics | Tryngolza for Dyslipidemia / Hypercholesterolemia | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 03/31/2023 | Subscribers Only | Subscribers Only | Trial Announcement - Initiation |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/25/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 06/26/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 09/08/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |